🔗 Visit the ClinicalTrials.gov page for NCT01672450
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. | J Leukoc Biol | 2013 | 1.90 |
| 2 | Intratumoral immunization: a new paradigm for cancer therapy. | Clin Cancer Res | 2014 | 1.24 |
| 3 | Checkpoint modulation in melanoma: an update on ipilimumab and future directions. | Curr Oncol Rep | 2013 | 0.94 |
| 4 | Prime time for immune-checkpoint targeted therapy at ASCO 2015. | Oncoimmunology | 2015 | 0.75 |
| 5 | Intratumoral checkpoint subversion as a strategy for minimizing adverse effects: Harvesting the power of TILs without harvesting TILs. | Oncoimmunology | 2014 | 0.75 |